{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:08:14Z","timestamp":1792613294978,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment with Phosphodiesterase Type 5 inhibitors (PDE5is) has shown promise in managing Peyronie\u2019s disease (PD) during its active phase. In a retrospective cohort study of 133 PD patients, we compared daily PDE5i treatment (sildenafil 25\u2009mg or tadalafil 5\u2009mg) in Group 1 (n\u2009=\u2009101) to no treatment in Group 2 (n\u2009=\u200932). The mean age \u00b1 SD was 58.5\u2009\u00b1\u200910, (range: 29-77) years in Group 1 and 59\u2009\u00b1\u200913.7 years (range: 23-80) in Group 2 (p\u2009=\u20090.5). Mean symptom onset-to-visit time was 10.6\u2009\u00b1\u20097.2 months (range: 1-37) in Group 1 and 11\u2009\u00b1\u20096.3 months (range 3-27) in Group 2 (p\u2009=\u20090.5). Mean penile curvature change was +0.87\u00b0 (95% CI: -1.8, 3.5) in Group 1 and +5.72\u00b0 (95% CI: 1.4, 10) in Group 2 (p\u2009=\u20090.07) between first and last observations. Group 1 experienced shorter mean pain duration (9.1\u2009\u00b1\u20094.7 months, range: 2.5-24) than Group 2 (12.2\u2009\u00b1\u20096.5 months, range: 5-28) (p\u2009=\u20090.04). When controlling for baseline curvature and symptom onset-to-visit time, there were no differences between groups (-4.7, 95% CI: -10, 0.6) (p\u2009=\u20090.08). In conclusion, continuous PDE5i treatment did not affect PD curvature progression but showed a promising effect on pain.<\/jats:p>","DOI":"10.1038\/s41443-023-00810-5","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T13:01:29Z","timestamp":1705410089000},"page":"151-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie\u2019s Disease: A retrospective cohort study"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-8944","authenticated-orcid":false,"given":"Emil","family":"Durukan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Kraglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shad Azad","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Thorkilgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-1413","authenticated-orcid":false,"given":"Christian Fuglesang Skj\u00f8dt","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8963-4581","authenticated-orcid":false,"given":"Mikkel","family":"Fode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"810_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/sj.ijir.3901518","volume":"19","author":"M Arafa","year":"2007","unstructured":"Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie\u2019s disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007;19:213\u20137.","journal-title":"Int J Impot Res"},{"key":"810_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0022-5347(17)37988-0","volume":"146","author":"MB Lindsay","year":"1991","unstructured":"Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie\u2019s disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991;146:1007\u20139.","journal-title":"J Urol"},{"key":"810_CR3","doi-asserted-by":"publisher","first-page":"100398","DOI":"10.1016\/j.esxm.2021.100398","volume":"9","author":"JM Flores","year":"2021","unstructured":"Flores JM, Salter CA, Nascimento B, Terrier JE, Taniguchi H, Bernie HL, et al. The prevalence and predictors of penile pain in men with Peyronie\u2019s disease. Sex Med. 2021;9:100398.","journal-title":"Sex Med"},{"key":"810_CR4","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"JP Mulhall","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie\u2019s disease. J Urol. 2006;175:2115\u20138.","journal-title":"J Urol"},{"key":"810_CR5","doi-asserted-by":"crossref","unstructured":"Berookhim BM, Choi J, Alex B, Mulhall JP. Deformity stabilization and improvement in men with untreated Peyronie\u2019s disease. 2013.","DOI":"10.1111\/bju.12346"},{"key":"810_CR6","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0022-5347(17)39746-X","volume":"144","author":"MK Gelbard","year":"1990","unstructured":"Gelbard MK, Dorey F, James K. The natural history of Peyronie\u2019s disease. J Urol. 1990;144:1376\u20139.","journal-title":"J Urol"},{"key":"810_CR7","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","volume":"168","author":"A Kadioglu","year":"2002","unstructured":"Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie\u2019s disease. J Urol. 2002;168:1075\u20139.","journal-title":"J Urol"},{"key":"810_CR8","unstructured":"Salonia A, Minhas S, Bettocchi C, Capogrosso P, Corona G, Hatzichristodoulou G, et al. Sexual and Reproductive Health. EAU Guidel. Edn. Present. EAU Annu. Congr. Milan 2023. Accessed April 24, 2023. https:\/\/uroweb.org\/guidelines\/sexual-and-reproductive-health\/chapter\/citation-information"},{"key":"810_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","volume":"97","author":"MG Ferrini","year":"2006","unstructured":"Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie\u2019s disease. BJU Int. 2006;97:625\u201333.","journal-title":"BJU Int"},{"key":"810_CR10","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/j.1743-6109.2011.02217.x","volume":"8","author":"E Chung","year":"2011","unstructured":"Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8:1472\u20137.","journal-title":"J Sex Med"},{"key":"810_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","volume":"183","author":"U Ozturk","year":"2014","unstructured":"Ozturk U, Yesil S, Goktug HNG, Gucuk A, Tuygun C, Sener NC, et al. Effects of sildenafil treatment on patients with Peyronie\u2019s disease and erectile dysfunction. Ir J Med Sci. 2014;183:449\u201353.","journal-title":"Ir J Med Sci"},{"key":"810_CR12","doi-asserted-by":"publisher","unstructured":"Spirito L, Manfredi C, La Rocca R, Napolitano L, Di Girolamo A, Capece M, et al. Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie\u2019s disease: a retrospective comparative analysis. Int J Impot Res. 2022. https:\/\/doi.org\/10.1038\/s41443-022-00651-8","DOI":"10.1038\/s41443-022-00651-8"},{"key":"810_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","volume":"9","author":"EG Valente","year":"2003","unstructured":"Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie\u2019s fibrotic plaque and related fibroblast cultures. Nitric oxide Biol Chem. 2003;9:229\u201344.","journal-title":"Nitric oxide Biol Chem"},{"key":"810_CR14","doi-asserted-by":"publisher","first-page":"5S","DOI":"10.1046\/j.0306-5251.2001.00027.x","volume":"53","author":"DJ Nichols","year":"2002","unstructured":"Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53:5S.","journal-title":"Br J Clin Pharmacol"},{"key":"810_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2125.2005.02553.x","volume":"61","author":"ST Forgue","year":"2006","unstructured":"Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61:280.","journal-title":"Br J Clin Pharmacol"},{"key":"810_CR16","first-page":"407","volume":"38","author":"SA Huang","year":"2013","unstructured":"Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. Pharm Ther. 2013;38:407.","journal-title":"Pharm Ther"},{"key":"810_CR17","first-page":"1","volume":"00","author":"MM Ilg","year":"2023","unstructured":"Ilg MM, Ralph DJ, Cellek S. Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie\u2019s disease. J Sex Med. 2023;00:1\u201310.","journal-title":"J Sex Med"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00810-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:02:55Z","timestamp":1711105375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-023-00810-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1038\/s41443-023-00810-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3170469\/v1","asserted-by":"object"}]},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}